KI-67 in pituitary neoplasms: A review - Part I

Neurosurgery

Volumn 65, Issue 3, 2009, Pages 429-437

  Salehi, Fateme ^a   Agur, Anne ^b   Scheithauer, Bernd W ^c   Kovacs, Kalman ^a   Lloyd, Ricardo V ^c   Cusimano, Michael ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

Invasion; Ki 67; MIB 1; Pituitary tumors; Recurrence; Tumor size

Indexed keywords

BETA CATENIN; BROMOCRIPTINE; CORTICOTROPIN; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; GROWTH HORMONE; KI 67 ANTIGEN; OCTREOTIDE; PROLACTIN; PROTEIN P27; UVOMORULIN; VASCULOTROPIN;

ANTIGEN EXPRESSION; CANCER INVASION; CELL CYCLE REGULATION; CELL LABELING; CELL PROLIFERATION; CORTICOTROPIN BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE MARKER; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; ONCOGENE C MYC; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR RECURRENCE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; PITUITARY NEOPLASMS;

EID: 69549135981     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000349930.66434.82     Document Type: Review

References (56)

1. Abe T, Sanno N, Osamura YR, Matsumoto K: Proliferative potential in pituitary adenomas: Measurement by monoclonal antibody MIB-1. Acta Neurochir (Wien) 139:613-618, 1997. (Pubitemid 27298211)
2. Al-Shraim M, Asa SL: The 2004 World Health Organization classification of pituitary tumors: What is new? Acta Neuropathol 111:1-7, 2006.
3. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S: The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90:6290-6295, 2005. (Pubitemid 41606558)
4. Botelho CH, Magalhães AV, Mello PA, Schmitt FC, Casulari LA: Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr 64:60-66, 2006.
5. Bottoni A, Zatelli MC, Ferracin M, Tagliati F, Piccin D, Vignali C, Calin GA, Negrini M, Croce CM, Degli Uberti EC: Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas. J Cell Physiol 210:370-377, 2007. (Pubitemid 44956882)
6. Burger PC, Shibata T, Kleihues P: The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: Application to surgical neuropathology. Am J Surg Pathol 10:611-617, 1986. (Pubitemid 16011866)
7. Daita G, Yonemasu Y: Dural invasion and proliferative potential of pituitary adenomas. Neurol Med Chir (Tokyo) 36:211-214, 1996. (Pubitemid 26138034)
8. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J: Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102-2107, 1997. (Pubitemid 27287568)
9. Dubois S, Guyétant S, Menei P, Rodien P, Illouz F, Vielle B, Rohmer V: Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 157:141-147, 2007. (Pubitemid 47233117)
10. Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T: The correlation of Ki-67 staining indices with tumour doubling times in regrowing nonfunctioning pituitary adenomas. Acta Neurochir (Wien) 138:1449-1455, 1996. (Pubitemid 27010696)
11. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P: Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: A clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65:536-543, 2006. (Pubitemid 44414280)
12. Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H: Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 2:365-371, 1984. (Pubitemid 15151580)
13. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20, 1983. (Pubitemid 13179545)
14. Gong J, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Lopes MB, Hussaini IM, Laws ER: Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary 11:37-48, 2007. (Pubitemid 351168083)
15. Hentschel SJ, McCutcheon E, Moore W, Durity FA: P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 30:215-219, 2003. (Pubitemid 37064515)
16. Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Mönting J, Reincke M: Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: Correlation with growth velocity and invasiveness. J Neurosurg 99:674-679, 2003. (Pubitemid 37159044)
17. Ibrahim AE, Pickering RM, Gawne-Cain ML, King S, Lees PD, Ellison DW: Indices of apoptosis and proliferation as potential prognostic markers in nonfunctioning pituitary adenomas. Clin Neuropathol 23:8-15, 2004. (Pubitemid 38173350)
18. Deleted in proof.
19. Iuchi S, Saeki N, Uchino Y, Higuchi Y, Tatsuno I, Nakamura S, Yasuda T, Yamaura A: Cavernous sinus invasion and tumor proliferative potential of growth hormone-producing pituitary tumors. Endocr J 47 [Suppl]:S77-S79, 2000. (Pubitemid 30243440)
20. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G: A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: Secreting versus non-secreting adenomas. Endocr Relat Cancer 9:103-113, 2002. (Pubitemid 34832163)
21. Kleinschmidt-DeMasters BK: Subtyping does matter in pituitary adenomas. Acta Neuropathol 111:84-85, 2006.
22. Knosp E, Steiner E, Kitz K, Matula C: Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610-618, 1993. (Pubitemid 23292752)
23. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB: Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 87:2635-2643, 2002. (Pubitemid 34655325)
24. Landolt AM, Shibata T, Kleihues P: Growth rate of human pituitary adenomas. J Neurosurgery 67:803-806, 1987. (Pubitemid 18005523)
25. Lath R, Chacko G, Chandy MJ: Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody. Neurol India 49:144-147, 2001. (Pubitemid 32691251)
26. Laws ER Jr, Lopes MB: The new WHO classification of pituitary tumors: Highlights and areas of controversy. Acta Neuropathol 111:80-81, 2006. (Pubitemid 43013838)
27. Lloyd RV, Kovacs K, Young WF Jr, Farrel WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E: Tumours of the pituitary, in DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds): World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of Endocrine Organs. Lyon, IARC, 2004, pp 10-47.
28. Lloyd RV, Vidal S, Horvath E, Kovacs K, Scheithauer B: Angiogenesis in normal and neoplastic pituitary tissues. Microsc Res Tech 60:244-250, 2003. (Pubitemid 36125713)
29. Losa M, Barzaghi RL, Mortini P, Franzin A, Mangili F, Terreni MR, Giovanelli M: Determination of the proliferation and apoptotic index in adrenocorticotropin- secreting pituitary tumors: Comparison between micro- and macroadenomas. Am J Pathol 156:245-251, 2000. (Pubitemid 30644458)
30. Mahta A, Haghpanah V, Lashkari A, Heshmat R, Larijani B, Tavangar SM: Non-functioning pituitary adenoma: Immunohistochemical analysis of 85 cases. Folia Neuropathol 45:72-77, 2007. (Pubitemid 47082827)
31. Mastronardi L, Guiducci A, Puzzilli F: Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1:12, 2001. (Pubitemid 38846507)
32. Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G: Ki-67 labelling index and invasiveness among anterior pituitary adenomas: Analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 52:107-111, 1999. (Pubitemid 29062344)
33. Mizoue T, Kawamoto H, Arita K, Kurisu K, Tominaga A, Uozumi T: MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochir (Wien) 139:426-432, 1997. (Pubitemid 27229189)
34. Nakabayashi H, Sunada I, Hara M: Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem 49:1193-1194, 2001. (Pubitemid 32800543)
35. Niveiro M, Aranda FI, Payá A, Boix E, Peiró G, Picó A: Oncocytic transformation in pituitary adenomas: Immunohistochemical analyses of 65 cases. Arch Pathol Lab Med 128:776-780, 2004. (Pubitemid 38856888)
36. Paek KI, Kim SH, Song SH, Choi SW, Koh HS, Youm JY, Kim Y: Clinical significance of Ki-67 labeling index in pituitary macroadenoma. J Korean Med Sci 20:489-494, 2005.
37. Pan LX, Chen ZP, Liu YS, Zhao JH: Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol 74:71-76, 2005. (Pubitemid 41194534)
38. Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP: Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res 37:235-243, 2004.
39. Prevedello DM, Jagannathan J, Jane JA Jr, Lopes MB, Laws ER Jr: Relevance of high Ki-67 in pituitary adenomas. Case report and review of the literature. Neurosurg Focus 19:E11, 2005.
40. Qian ZR, Li CC, Yamasaki H, Mizusawa N, Yoshimoto K, Yamada S, Tashiro T, Horiguchi H, Wakatsuki S, Hirokawa M, Sano T: Role of E-cadherin, alpha-, beta-, and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Mod Pathol 15:1357-1365, 2002. (Pubitemid 35463005)
41. Ruebel KH, Leontovich AA, Jin L, Stilling GA, Zhang H, Qian X, Nakamura N, Scheithauer BW, Kovacs K, Lloyd RV: Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression. Endocrine 29:435-444, 2006. (Pubitemid 44358833)
42. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr: Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59:341-353, 2006.
43. Shibuya M, Saito F, Miwa T, Davis RL, Wilson CB, Hoshino T: Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol (Berl) 84:178-183, 1992.
44. Suliman M, Royds J, Cullen D, Timperley W, Powell T, Battersby R, Jones TH: Mdm2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol (Oxf) 54:317-325, 2001. (Pubitemid 32234195)
45. Suzuki M, Minematsu T, Oyama K, Tahara S, Miyai S, Sanno N, Osamura RY, Teramoto A: Expression of proliferation markers in human pituitary incidentalomas. Endocr Pathol 17:263-275, 2006. (Pubitemid 46279674)
46. Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S: Growth pattern and rate in residual nonfunctioning pituitary adenomas: Correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 98:359-365, 2003. (Pubitemid 36151032)
47. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB-1 antibody. Neurosurgery 38:99-107, 1996. (Pubitemid 26002389)
48. Turner HE, Wass JA: Are markers of proliferation valuable in the histological assessment of pituitary tumours? Pituitary 1:147-151, 1999.
49. Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JA, Harris AL: Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: Relationship to tumour behaviour. Br J Cancer 82:1441-1445, 2000. (Pubitemid 30175911)
50. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fèvre-Montange M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J, Trouillas J: A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer 14:887-900, 2007. (Pubitemid 350074076)
51. Wolfsberger S, Kitz K, Wunderer J, Czech T, Boecher-Schwarz HG, Hain - fellner JA, Knosp E: Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas. Acta Neurochir (Wien) 146:1323-1328, 2004. (Pubitemid 40064404)
52. Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Böcher-Schwarz HG, Hainfellner J, Knosp E: Expression of cell proliferation markers in pituitary adenomas-Correlation and clinical relevance of MIB-1 and antitopoisomerase- IIalpha. Acta Neurochir (Wien) 146:831-839, 2004. (Pubitemid 39024942)
53. Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T: A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61:580-585, 2007. (Pubitemid 47442650)
54. Yokoyama S, Hirano H, Moroki K, Goto M, Imamura S, Kuratsu JI: Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive? Neurosurgery 49:857-863, 2001. (Pubitemid 32927957)
55. Yonezawa K, Tamaki N, Kokunai T: Clinical features and growth fractions of pituitary adenomas. Surg Neurol 48:494-500, 1997. (Pubitemid 27463625)
56. Zhao D, Tomono Y, Nose T: Expression of P27kip1 and Ki-67 in pituitary adenomas: An investigation of marker of adenoma invasiveness. Acta Neurochir (Wien) 141:187-192, 1999. (Pubitemid 29099590)